世界の個別化医療市場2022-2029:製品別(個別化医療診断、個別化医療治療薬、個別化医療治療、個別化栄養・健康)、地域別

【英語タイトル】Global Personalized Medicine Market Size study & Forecast, by Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness) and Regional Analysis, 2022-2029

Bizwit Research & Consultingが出版した調査資料(BZW23MA036)・商品コード:BZW23MA036
・発行会社(調査会社):Bizwit Research & Consulting
・発行日:2023年4月10日
・ページ数:約200
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用、印刷不可)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Enterprisewide(同一法人内共有可)USD6,250 ⇒換算¥925,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Bizwit Research社の本調査資料では、2021年に5,143.3億ドルであった世界の個別化医療市場規模が、2022年〜2029年にかけて年平均6.95%で成長すると予測しています。本資料は、個別化医療の世界市場について市場実態を明らかにするとともに、今後の動向を展望したレポートです。エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析(新型コロナウイルス感染症の影響)、製品別(個別化医療診断、個別化医療治療薬、個別化医療治療、個別化栄養・健康)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、その他地域)分析、競争分析、調査プロセスなどの項目で構成されています。また、主要参入企業として、GE Healthcare、Illumina, Inc.、ASURAGEN, INC.、Abbott、Dako A/S、Exact Sciences Corporation、Danaher Corporation (Cepheid, Inc.)、Decode Genetics, Inc.、QIAGEN、Exagen Inc.などの情報が含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析(新型コロナウイルス感染症の影響)
・世界の個別化医療市場規模:製品別
- 個別化医療診断の市場規模
- 個別化医療治療薬の市場規模
- 個別化医療治療の市場規模
- 個別化栄養・健康の市場規模
・世界の個別化医療市場規模:地域別
- 北米の個別化医療市場規模
- ヨーロッパの個別化医療市場規模
- アジア太平洋の個別化医療市場規模
- 中南米の個別化医療市場規模
- その他地域の個別化医療市場規模
・競争分析
・調査プロセス

Global Personalized Medicine Market is valued approximately USD 514.33 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.95% over the forecast period 2022-2029. Personalised medicine, is also known as precision medicine, it divides people into distinct groups and then tailors medical decisions, therapies, practises, and/or products to each patient depending on that patient’s expected response or illness risk. The market is majorly driven by rising demand for novel drug discovery, rising number of cancer cases and other diseases. Along with this, growing number of clinical trials is driving the growth for the market over the forecast period 2022-2029. Moreover, rising initiatives by key market players is creating lucrative growth opportunity for the market over the period.

It is also projected that the rising prevalence of rare diseases will accelerate market expansion. The development of numerous individualized medical treatments and therapeutic activities has been made possible by advances in our understanding and correlation of the properties of the human genome. For instance, a research study conducted at the University of California, Irvine in September 2022 offered a unique method for treating inherited retinal diseases (IRDs) by applying precise genome editing that is highly tailored to the needs of an individual. Along with this, there are an increasing number of companion diagnostics that have received FDA approval. For example, Roche received U.S. FDA clearance in October 2020 to expand the use of the Cobas EGFR Mutation Test for the treatment of non-small cell lung cancer. However, the high cost of Personalized Medicine stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Personalized Medicine Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2021, North America had the largest share. This is linked to funding from large pharmaceutical companies and research organisations. All types of ailments are now best treated with personalised medicine, which is why drug discovery and research into any condition now include it. In the region, personalised medicine is advancing for diagnostic purposes. Due to rising demand for personalised diagnostics and novel treatment medications to combat the region’s rising disease prevalence, Asia Pacific is anticipated to have the fastest expanding segment over the course of the projection year.

Major market player included in this report are:
GE Healthcare
Illumina, Inc.
ASURAGEN, INC.
Abbott
Dako A/S
Exact Sciences Corporation
Danaher Corporation (Cepheid, Inc.)
Decode Genetics, Inc.
QIAGEN
Exagen Inc.

Recent Developments in the Market:
 In order to create personalised nutrition for healthcare providers and their subjects using a high-end technology interface, Panaceutics Nutrition and Viocare announced a collaborative agreement in January 2022. This agreement will combine Viocare’s nutrition assessment software with personalised nutrition supplementation to create an end-to-end service platform.
 Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) in Germany joined up in February 2022 to apply precision medicine in healthcare in strategic, structural, and content-specific ways.

Global Personalized Medicine Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Personalized Medicine Diagnostics
Personalized Medicine Therapeutics
Personalized Medical Care
Personalized Nutrition & Wellness

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

❖ レポートの目次 ❖

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Personalized Medicine Market, by Region, 2019-2029 (USD Billion)
1.2.2. Personalized Medicine Market, by Product, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Personalized Medicine Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Personalized Medicine Market Dynamics
3.1. Personalized Medicine Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing prevalence of rare disease
3.1.1.2. Growing number of clinical trials
3.1.1.3. Rising demand for novel drug discovery
3.1.2. Market Challenges
3.1.2.1. High cost of Personalized Medicine
3.1.3. Market Opportunities
3.1.3.1. Rising initiatives by key market players
Chapter 4. Global Personalized Medicine Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Personalized Medicine Market, by Product
6.1. Market Snapshot
6.2. Global Personalized Medicine Market by Product, Performance – Potential Analysis
6.3. Global Personalized Medicine Market Estimates & Forecasts by Product 2019-2029 (USD Billion)
6.4. Personalized Medicine Market, Sub Segment Analysis
6.4.1. Personalized Medicine Diagnostics
6.4.2. Personalized Medicine Therapeutics
6.4.3. Personalized Medical Care
6.4.4. Personalized Nutrition & Wellness
Chapter 7. Global Personalized Medicine Market, Regional Analysis
7.1. Personalized Medicine Market, Regional Market Snapshot
7.2. North America Personalized Medicine Market
7.2.1. U.S. Personalized Medicine Market
7.2.1.1. Product breakdown estimates & forecasts, 2019-2029
7.2.2. Canada Personalized Medicine Market
7.3. Europe Personalized Medicine Market Snapshot
7.3.1. U.K. Personalized Medicine Market
7.3.2. Germany Personalized Medicine Market
7.3.3. France Personalized Medicine Market
7.3.4. Spain Personalized Medicine Market
7.3.5. Italy Personalized Medicine Market
7.3.6. Rest of Europe Personalized Medicine Market
7.4. Asia-Pacific Personalized Medicine Market Snapshot
7.4.1. China Personalized Medicine Market
7.4.2. India Personalized Medicine Market
7.4.3. Japan Personalized Medicine Market
7.4.4. Australia Personalized Medicine Market
7.4.5. South Korea Personalized Medicine Market
7.4.6. Rest of Asia Pacific Personalized Medicine Market
7.5. Latin America Personalized Medicine Market Snapshot
7.5.1. Brazil Personalized Medicine Market
7.5.2. Mexico Personalized Medicine Market
7.6. Rest of The World Personalized Medicine Market

Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. GE Healthcare
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Product Summary
8.2.1.5. Recent Developments
8.2.2. Illumina, Inc.
8.2.3. ASURAGEN, INC.
8.2.4. Abbott
8.2.5. Dako A/S
8.2.6. Exact Sciences Corporation
8.2.7. Danaher Corporation (Cepheid, Inc.)
8.2.8. Decode Genetics, Inc.
8.2.9. QIAGEN
8.2.10. Exagen Inc.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption



★調査レポート[世界の個別化医療市場2022-2029:製品別(個別化医療診断、個別化医療治療薬、個別化医療治療、個別化栄養・健康)、地域別] (コード:BZW23MA036)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の個別化医療市場2022-2029:製品別(個別化医療診断、個別化医療治療薬、個別化医療治療、個別化栄養・健康)、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆